Allergan settles Restasis suit, grants authorized generic to Family Care

DUBLIN — Allergan and its subsidiaries on Monday announced that it has reached a settlement regarding its litigation with Famy Care Limited relating to Allergan's Restasis (cyclosporine ophthalmic emulsion) 0.05%.



The patents relative to Restasis are listed in the Orange Book and expire on Aug. 27, 2024, Allergan stated.



However, as a result of the settlement, all Famy Care litigation regarding Restasis patents will be dismissed and Famy Care will terminate its pending petitions for Inter Parties Review. Allergan will grant Famy Care a license to market a generic version of Restasis in the United States beginning on Feb. 27, 2024, or earlier under certain circumstances.



Additional details regarding the settlement were not disclosed.